Integrative Omics for Informed Drug Repurposing: Targeting CNS Disorders
Rammohan Shukla(University of Toledo), Robert E. McCullumsmith(Neurosciences Institute), Justin F. Creeden(University of Toledo), Hunter Eby(University of Toledo), Ali Sajid Imami(University of Toledo), Scott A. Miruzzi(University of Toledo), James Reigle(Cincinnati Children's Hospital Medical Center), Rawan Alnafisah(University of Toledo), Abdul‐rizaq Hamoud(ProMedica Toledo Hospital), Nicholas Henkel(University of Toledo), Jarek Meller(Cincinnati Children's Hospital Medical Center), Khaled Alganem(University of Toledo)
Cited by 3
Related Papers
Bilirubin in the Liver–Gut Signaling Axis
|Trends in Endocrinology and Metabolism|2018|254
Postmortem Brain: An Underutilized Substrate for Studying Severe Mental Illness
|Neuropsychopharmacology|2013|120
Biliverdin reductase and bilirubin in hepatic disease
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2018|100
Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator–activated receptor α
|Journal of Biological Chemistry|2020|97
Signature-based approaches for informed drug repurposing: targeting CNS disorders
|Neuropsychopharmacology|2020|68